How does lebrikizumab fit into proactive vs reactive AD treatment approaches?

Featuring Alexandra Golant, MD | Medical Director, Dermatology Faculty PracticeAssociate Director, Residency ProgramDepartment of DermatologyIcahn School of Medicine at Mount SinaiNew York, NY | Published April 01, 2025